Intestinal metabolism and transport of 5-aminosalicylate

被引:0
|
作者
Zhou, SY
Fleisher, D
Pao, LH
Li, C
Winward, B
Zimmermann, EM
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[3] Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to determine the characteristics of intestinal absorption and metabolism of B-aminosalicylic acid (5ASA). Regional perfusions of 5ASA in the anesthetized rat resulted in the appearance of N-acetyl-5-aminosalicylic acid in the intestinal lumen. Lumenal metabolite appearance was proportional to 5ASA permeability, which was 5-fold higher in the jejunum than in the ileum. Intestinal elimination significantly decreases 5ASA absorption at low lumenal drug concentrations and this process is saturated at high drug concentrations. Metabolite levels in intestinal tissue were higher than plasma levels at low perfusion drug concentrations, whereas the reverse was observed at high concentrations. Transport and metabolism of 5ASA was studied in Caco-2 monolayers. At low drug concentrations, 5ASA was preferentially transported in the basolateral (BL) to apical (AP) direction. With 5ASA incubation in either the AP or BL chamber, the N-acetyl metabolite appeared only in the AP compartment. Transport of N-acetyl-5-aminosalicylic acid was also exclusively observed in the BL to AP direction. Clinical data indicate that anti-inflammatory response to oral 5ASA correlates with the amount of BASA delivered to the intestinal tissue. This study shows that at lumenal levels below 200 mu g/ml (concentrations that are typically achieved by controlled release dosage forms), intestinal secretion of 5ASA accounts for more than 50% of the total elimination and can significantly affect tissue levels and, therefore, may be an important factor in determining the response to 5ASA therapy.
引用
收藏
页码:479 / 485
页数:7
相关论文
共 50 条
  • [31] Prospective experience of 5-aminosalicylate associated nephrotoxicity in the UK.
    Stevens, PE
    Logan, RF
    McIntyre, AS
    Muller, AF
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 454A - 454A
  • [32] 5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis
    Shimizu, Hirotaka
    Arai, Katsuhiro
    Tang, Julian
    Hosoi, Kenji
    Funayama, Rie
    PEDIATRICS INTERNATIONAL, 2017, 59 (05) : 583 - 587
  • [33] Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine
    Zhou, SY
    Piyapolrungroj, N
    Pao, LH
    Li, C
    Liu, GY
    Zimmermann, E
    Fleisher, D
    PHARMACEUTICAL RESEARCH, 1999, 16 (11) : 1781 - 1785
  • [34] Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance
    Marshall, JK
    Irvine, EJ
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1998, 12 (04): : 273 - 275
  • [35] 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease
    So, Kenji
    Bewshea, Claire M.
    Heap, Graham A.
    Muller, Andrew F.
    Delaney, Michael P.
    Daneshmend, Tawfique K.
    Hart, Ailsa L.
    Orchard, Timothy R.
    Irving, Peter M.
    D'Souza, Richard
    Mulgrew, Chris
    Kwan, Jonathan
    Silverberg, Mark S.
    Gearry, Richard B.
    Radford-Smith, Graham
    Watermeyer, Gillian
    D'Inca, Renata
    Annese, Vito
    Tsianos, Epameinondas V.
    Russell, Richard K.
    Wilson, David C.
    Parkes, Miles
    Satsangi, Jack
    Oram, Richard A.
    Weersma, Rinse K.
    Lawrance, Ian C.
    Holden, Arthur L.
    Lees, Charlie W.
    Ahmad, Tariq
    GASTROENTEROLOGY, 2013, 144 (05) : S112 - S112
  • [36] 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE
    So, K.
    Bewshea, C.
    Heap, G. A.
    Muller, A. F.
    Daneshmend, T. K.
    Hart, A. L.
    Orchard, T. R.
    Irving, P. M.
    Russell, R. K.
    Wilson, D. C.
    Parkes, M.
    Satsangi, J.
    Lees, C. W.
    Ahmad, T.
    GUT, 2013, 62 : A22 - A22
  • [37] Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease
    Noureldin, Mohamed
    Cohen-Mekelburg, Shirley
    Mahmood, Asadullah
    Stidham, Ryan
    Higgins, Peter D. R.
    Govani, Shail
    Deshpande, Amar R.
    Waljee, Akbar K.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (04) : 516 - 521
  • [38] 5-Aminosalicylate intolerance is a risk factor for hospitalization in patients with UC
    Yusuke, Yoshimatsu
    Shinta, Mizuno
    Makoto, Naganuma
    Tomohiro, Fukuda
    Ena, Nomura
    Kosuke, Yoshida
    Satoko, Umeda
    Keiko, Ono
    Shinya, Sugimoto
    Kosaku, Nanki
    Yohei, Mikami
    Kayoko, Kimura
    Makoto, Mutaguchi
    Tomohisa, Sujino
    Kaoru, Takabayashi
    Haruhiko, Ogata
    Yasushi, Iwao
    Takanori, Kanai
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S6 - S7
  • [39] Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients
    Fujii, T.
    Hibiya, S.
    Maeyashiki, C.
    Saito, E.
    Takenaka, K.
    Motobayashi, M.
    Shimizu, H.
    Nagahori, M.
    Ohtsuka, K.
    Kurosaki, M.
    Yauchi, T.
    Watanabe, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S409 - S410
  • [40] Synthesis and characterization of rare earth solid complexes with sodium 5-aminosalicylate
    Zhang, XY
    Li, SJ
    Lei, XF
    Ma, JX
    JOURNAL OF RARE EARTHS, 2005, 23 (02) : 143 - 147